Edition:
India

Lexicon Pharmaceuticals Inc (LXRX.OQ)

LXRX.OQ on NASDAQ Stock Exchange Global Select Market

6.20USD
1:30am IST
Change (% chg)

$-1.74 (-21.91%)
Prev Close
$7.94
Open
$7.91
Day's High
$8.04
Day's Low
$4.25
Volume
1,135,182
Avg. Vol
237,190
52-wk High
$13.97
52-wk Low
$4.25

Latest Key Developments (Source: Significant Developments)

Lexicon Pharmaceuticals Reports Q4 Loss Per Share Of $0.16
Wednesday, 13 Mar 2019 

March 13 (Reuters) - Lexicon Pharmaceuticals Inc ::Q4 SALES $17.1 MILLION .LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE.Q4 LOSS PER SHARE $0.16.Q4 REVENUE ESTIMATE $13.3 MILLION -- REFINITIV IBES DATA.Q4 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA.SOTAGLIFLOZIN IN TYPE 1 DIABETES: MARCH 22 PDUFA DATE IN U.S., EUROPEAN COMMISSION DECISION EXPECTED IN Q2 2019.  Full Article

Lexicon Pharmaceuticals Q4 Loss Per Share $0.16
Wednesday, 13 Mar 2019 

March 13 (Reuters) - Lexicon Pharmaceuticals Inc ::LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE.Q4 SALES $25 MILLION.Q4 LOSS PER SHARE $0.16.Q4 REVENUE ESTIMATE $13.3 MILLION -- REFINITIV IBES DATA.Q4 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA.SOTAGLIFLOZIN IN TYPE 1 DIABETES: MARCH 22 PDUFA DATE IN U.S., EUROPEAN COMMISSION DECISION EXPECTED IN Q2 2019.  Full Article

Sanofi SA Says European Commission To Make Decision On Marketing Authorization Application For Sotagliflozin In EU In Coming Months
Friday, 1 Mar 2019 

March 1 (Reuters) - Sanofi SA ::SANOFI : CHMP RECOMMENDS ZYNQUISTATM (SOTAGLIFLOZIN) FOR THE TREATMENT OF ADULTS WITH TYPE 1 DIABETES.SANOFI - EUROPEAN COMMISSION IS EXPECTED TO MAKE A FINAL DECISION ON MARKETING AUTHORIZATION APPLICATION FOR SOTAGLIFLOZIN IN EU IN COMING MONTHS.  Full Article

Lexicon Pharmaceuticals reports Q3 loss per share $0.29
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Lexicon Pharmaceuticals Inc :Lexicon Pharmaceuticals reports third quarter 2017 financial results and provides a business update.Q3 loss per share $0.29.Q3 revenue $26.9 million versus I/B/E/S view $27.7 million.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.  Full Article

FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

March 22 The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday.